Ring In Acid Moiety Patents (Class 514/484)
-
Publication number: 20080161393Abstract: Methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat migraine, fibromyalgia, amyotrophic lateral sclerosis, irritable bowel syndrome, social phobia, Parkinson's disease, asthma, cough, or chronic obstructive pulmonary disease, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating migraine, fibromyalgia, amyotrophic lateral sclerosis, irritable bowel syndrome, social phobia, Parkinson's disease, asthma, cough, or chronic obstructive pulmonary disease are disclosed.Type: ApplicationFiled: December 6, 2007Publication date: July 3, 2008Inventors: Ronald W. Barrett, Kenneth C. Cundy
-
Publication number: 20080153898Abstract: Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl)-cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for oral and topical administration and for administration using sustained release dosage forms are also disclosed.Type: ApplicationFiled: October 12, 2007Publication date: June 26, 2008Inventors: Noa Zerangue, Bernd Jandeleit, Yunxiao Li, Mark A. Gallop
-
Patent number: 7329689Abstract: A compound having formula (I) and a process for the preparation thereof are described.Type: GrantFiled: June 10, 2005Date of Patent: February 12, 2008Assignee: Italfarmaco SpAInventors: Massimo Pinori, Paolo Mascagni
-
Patent number: 7235586Abstract: The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives. The compounds used in accordance with the invention are represented by the following formula I: wherein a wavy segments indicate either the alpha (?) or beta (?) configuration; the dashed bond represents a double bond or a single bond; U, Y, X, R1, Ar, n, x and y are as defined in the specification.Type: GrantFiled: September 9, 2003Date of Patent: June 26, 2007Assignee: Allergan, Inc.Inventors: David W. Old, Robert M. Burk
-
Patent number: 7176201Abstract: Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH2, O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R1 and R2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R1 and R2 is absent, and that if Z is N, optionally R1 and R2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which theyType: GrantFiled: October 7, 2003Date of Patent: February 13, 2007Assignees: The Regents of the University of California, Universita Degli Studi di Parma, Universita Degli Studi di UrbinoInventors: Daniele Piomelli, Andrea Duranti, Andrea Tontini, Marco Mor, Giorgio Tarzia
-
Patent number: 7087643Abstract: This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1–C4 alkyl; wherein C1–C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of hydrogen, halogen, C1–C4 alkyl, C1–C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: June 16, 2004Date of Patent: August 8, 2006Assignee: Ortho-McNeil Pharmaceutical Inc.Inventors: Ellen C. Codd, Carlos R. Plata-Salaman, Boyu Zhao
-
Patent number: 7034057Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-? or combinations thereof.Type: GrantFiled: November 19, 2003Date of Patent: April 25, 2006Assignee: Schering CorporationInventors: Zhaoning Zhu, Robert Mazzola, Zhuyan Guo, Brian J. Lavey, Lisa Sinning, Joseph Kozlowski, Brian McKittrick, Neng-Yang Shih
-
Patent number: 6986898Abstract: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective amount of the above synergistic and residual pesticidal compositions to a locus where pest control is desired.Type: GrantFiled: June 28, 1999Date of Patent: January 17, 2006Assignee: Ecosmart Technologies, Inc.Inventor: Steven M. Bessette
-
Patent number: 6833387Abstract: The use of a 3-substituted indole compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof; X is CH2 or SO2 and R1, R2, R3, R4, R5, R6 and R7 are certain specified organic moieties, for use in the preparation of a medicament for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis. Pharmaceutical compositions containing certain compounds of formula (I) and novel compounds of formula (I) are also described and claimed.Type: GrantFiled: October 2, 2001Date of Patent: December 21, 2004Assignee: AstraZeneca ABInventors: Alan W. Faull, Jason Kettle
-
Patent number: 6825224Abstract: The present invention relates to novel compounds, methods of preparing these compounds, and pharmaceutical compositions comprising these compounds. These compounds are carbamate prodrugs that convert to active inhibitors of the IMPDH enzyme in vivo. The compounds and pharmaceutical compositions of this invention are particularly well suited for activation and subsequent inhibition of the IMPDH enzyme activity. Consequently, these prodrugs may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds and compositions of this invention.Type: GrantFiled: April 17, 2002Date of Patent: November 30, 2004Assignee: Vertex Pharmaceuticals, IncorporatedInventors: Dean P. Stamos, Randy S. Bethiel
-
Patent number: 6815464Abstract: This invention is directed to a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).Type: GrantFiled: February 21, 2002Date of Patent: November 9, 2004Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
-
Publication number: 20040209948Abstract: Disclosed are CCR8 inhibitors represented by Structural Formulas (I): 1Type: ApplicationFiled: December 23, 2003Publication date: October 21, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Bing Guan, Charles Minor, Mingshi Dai, Shomir Ghosh, Tracy J. Jenkins, Gang Li, Douglas F. Burdi, Robert A. Bennett
-
Patent number: 6777572Abstract: Compounds characterized generally as propargyl glycine amino propargyl diol derivatives are useful for treatment of renal failure.Type: GrantFiled: November 28, 2001Date of Patent: August 17, 2004Assignee: Pharmacia Corporation (of Pfizer Inc.)Inventors: Gunnar J. Hanson, John S. Baran
-
Publication number: 20040147455Abstract: The present invention relates generally to prodrugs of fused GABA analogs, pharmaceutical compositions of prodrugs of fused GABA analogs, methods of making prodrugs of fused GABA analogs and methods of using prodrugs of fused GABA analogs and pharmaceutical compositions of prodrugs of fused GABA analogs to treat or prevent various diseases.Type: ApplicationFiled: December 11, 2003Publication date: July 29, 2004Inventor: Mark A. Gallop
-
Publication number: 20040138262Abstract: The present invention provides compounds of the formula 1Type: ApplicationFiled: July 8, 2003Publication date: July 15, 2004Applicant: Pfizer Inc.Inventors: Yves A. Chantigny, Edward F. Kleinman, Ralph P. Robinson
-
Publication number: 20040132809Abstract: A cell adhesion inhibitor of the general formula:Type: ApplicationFiled: October 3, 2003Publication date: July 8, 2004Applicant: Biogen, Inc.Inventors: Daniel Scott, Wen-Cherng Lee, Russell C. Petter, Mark Cornebise
-
Publication number: 20040127487Abstract: An agent comprising the benzoic acid of formula (I) 1Type: ApplicationFiled: December 18, 2003Publication date: July 1, 2004Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kousuke Tani, Kaoru Kobayashi, Takayuki Maruyama
-
Patent number: 6756511Abstract: Gamma-secretase inhibitors, useful in the treatment or prevention of Alzheimer's disease, are disclosed. The preferred compounds have, as the central portion of the molecule, the structure (a) and are di-astereoisomers of known protease inhibitors.Type: GrantFiled: July 18, 2002Date of Patent: June 29, 2004Assignee: Merck Sharp & Dohme LimitedInventors: Jose Luis Castro Pineiro, Timothy Harrison, Peter Alan Hunt, Alan John Nadin
-
Publication number: 20040116489Abstract: The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.Type: ApplicationFiled: December 8, 2003Publication date: June 17, 2004Inventors: Steven Marc Massey, James Allen Monn, Matthew John Valli, Lourdes Prieto
-
Publication number: 20040110830Abstract: The present invention relates to an inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, specific hydroxyformamidine derivatives or pharmaceutically-acceptable salts thereof. The inhibitors according to the present invention are useful as therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases.Type: ApplicationFiled: July 1, 2003Publication date: June 10, 2004Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Masakazu Sato, Noriyuki Miyata, Takaaki Ishii, Yuko Kobayashi, Hideaki Amada
-
Publication number: 20040102418Abstract: This invention relates to compounds of the Formula (I): 1Type: ApplicationFiled: November 19, 2003Publication date: May 27, 2004Inventors: Zhoaning Zhu, Robert Mazzola, Zhuyan Guo, Brian J. Lavey, Lisa Sinning, Joseph Kozlowski, Brian McKittrick, Neng-Yang Shih
-
Publication number: 20040072880Abstract: Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.Type: ApplicationFiled: January 31, 2003Publication date: April 15, 2004Inventors: John Lloyd, Yoon T. Jeon, Heather Finlay, Lin Yan, Michael F. Gross, Serge Beaudoin
-
Patent number: 6717012Abstract: The invention provides novel adamantane compounds having one of the following formulas: wherein: R1 and R3 are H, OH, alkyl, cycloalkyl, amino or aryl, and can be the same or different; R2 is H, NH2, alkyl, OH, COOH, amino, amide, or carbamate; R4-R8 are H, OH, NH2, alkyl, OH, COOH, ester, amino, amide, or alkyloxy, and can be the same or different; R9-R14 are H, alkyl, or phenyl, and can be the same or different; and wherein when any of R1-R8 is amino, the compounds are the free bases and their acid addition salts. The present invention also relates to compositions and methods for treating and/or preventing neurological and inflammatory disorders in a patient by administering a therapeutically effective amount of the compounds of formula (I), (II) or (III) and a pharmaceutically acceptable carrier.Type: GrantFiled: April 2, 2002Date of Patent: April 6, 2004Assignee: NeuroMolecular, Inc.Inventors: Yuqiang Wang, James W. Larrick
-
Publication number: 20040063781Abstract: 1Type: ApplicationFiled: October 14, 2003Publication date: April 1, 2004Inventors: Benjamin Pelcman, Annika Gustafsson, Philip R Kym
-
Publication number: 20040063698Abstract: The present invention provides compounds of Formula (I): 1Type: ApplicationFiled: July 31, 2003Publication date: April 1, 2004Inventor: Thomas P. Maduskuie
-
Patent number: 6696497Abstract: A fungicidal composition comprises an acceptable carrier and/or surface active agent and a synergistically effective amount of (a) at least one benzophenone of formula I wherein R1, R2, R3, R4, R5, R6, R7, m and n have the meaning given; and at least one compound of formula II in which Ar and R8 have the meaning given. The composition is useful in a method of controlling the growth of phytopathogenic fungi at a locus. The method comprises applying synergistically effective amounts of (a) and (b) to the locus.Type: GrantFiled: February 13, 2001Date of Patent: February 24, 2004Assignee: BASF AktiengesellschaftInventors: Ewald Sieverding, Gunter Reichert
-
Publication number: 20040029960Abstract: The present invention relates to compositions comprising certain active compounds which are suitable as repellents, and to their use for preventing an infection of humans or of animals by the infectious stages of parasitic flatworms (platyhelminths).Type: ApplicationFiled: June 12, 2003Publication date: February 12, 2004Inventors: Achim Harder, Georg von Samson-Himmelstjerna, Bernd-Wieland Kruger, Heinz Mehlhorn, Jurgen Schmidt
-
Publication number: 20040029939Abstract: The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.Type: ApplicationFiled: November 4, 2002Publication date: February 12, 2004Inventors: Dean Stamos, Martin Trudeau, Scott Bethiel, Steven Ronkin, Michael Badia, Jeffrey Saunders
-
Patent number: 6667414Abstract: Compounds characterized generally as propargyl glycine amino propargyl diol derivatives are useful as renin inhibitors for the treatment of hypertension.Type: GrantFiled: November 28, 2001Date of Patent: December 23, 2003Assignee: Pharmacia CorporationInventors: Gunnar J. Hanson, John S. Baran
-
Publication number: 20030216434Abstract: The present application describes modulators of MCP-1 of formula (I): 1Type: ApplicationFiled: March 7, 2003Publication date: November 20, 2003Inventor: Robert J. Cherney
-
Publication number: 20030203915Abstract: The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent.Type: ApplicationFiled: April 7, 2003Publication date: October 30, 2003Inventors: Xinqin Fang, David S. Garvey, Ricky D. Gaston, Chia-En Lin, Ramani R. Ranatunga, Stewart K. Richardson, Tiansheng Wang, Weiheng Wang, Shiow-Jyi Wey
-
Publication number: 20030187037Abstract: Novel compounds of the formula I, in which R, R1 and R2 are as defined in patent claim 1, are inhibitors of coagulation factor Xa and VIIa and can be employed for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexis, angina pectoris, restenosis after angioplasty, claudicatio intermittens, tumours, tumour diseases and/or tumour metastases.Type: ApplicationFiled: January 29, 2003Publication date: October 2, 2003Inventors: Werner Mederski, Horst Juraszyk, Dieter Dorsch, Christos Tsaklakidis, Johannes Gleitz, Christopher Barnes
-
Publication number: 20030171303Abstract: The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amenable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug compounds and methods for synthesizing these 1-acyl-alkyl derivatives.Type: ApplicationFiled: June 11, 2002Publication date: September 11, 2003Inventors: Mark A. Gallop, Jia-Ning Xiang, Fenmei Yao, Laxminarayan Bhat, Cindy X. Zhou
-
Publication number: 20030158254Abstract: Methods of modifying therapeutic compounds such as drugs to be substrates for active transporters expressed in epithelial cells lining the lumen of the human colon are disclosed. The transporters expressed in the human colon include the sodium dependent multi-vitamin transporter (SMVT), and monocarboxylate transporters 1 and 4 (MCT 1 and MCT 4). The modified compounds can themselves be pharmacologically active, or upon cleavage of a chemical moiety after uptake from the colon, can be metabolized to form a compound that is pharmacologically active (e.g., a prodrug). The modified compounds disclosed herein are suitable for use in extended release oral dosage forms, particularly those that release drug over periods of greater than about 2-4 hours following administration.Type: ApplicationFiled: January 23, 2003Publication date: August 21, 2003Applicant: XenoPort, Inc.Inventors: Noa Zerangue, Kenneth C. Cundy, Mark A. Gallop
-
Publication number: 20030144214Abstract: GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present.Type: ApplicationFiled: November 21, 2002Publication date: July 31, 2003Inventors: David Clive Blakemore, Justin Stephen Bryans, Sophie Caroline Williams
-
Patent number: 6589986Abstract: This invention provides methods for treating, preventing or inhibiting anxiety, anxiety-related conditions and phobias in a mammal using compounds of the formula: wherein: R1 is H, alkyl, alkanoyl or the radical Ar; R2 is H or alkyl; R3 is alkoxy, NH2, alkylamino, dialkylamino, amino substituted by the radical Ar, alkyl, alkenyl, alkynyl, or the radicals Ar or ArO—; R4 is H, alkyl or the radical Ar; R5 is H or alkyl or the radical Ar; or a pharmaceutically acceptable salt or ester form thereof; Ar is an optionally substituted phenyl radical; and n is 0 or 1, or a pharmaceutically acceptable salt or ester form thereof, with the methods particularly including the use of N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also known as retigabine.Type: GrantFiled: December 17, 2001Date of Patent: July 8, 2003Assignee: WyethInventors: Mark R. Bowlby, Sharon Joy Rosenzweig-Lipson
-
Publication number: 20030045574Abstract: The invention provides novel adamantane compounds having one of the following formulas: 1Type: ApplicationFiled: April 2, 2002Publication date: March 6, 2003Inventors: Yuqiang Wang, James W. Larrick
-
Publication number: 20030032623Abstract: A purpose of the present invention is to provide TNF-&agr; production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis.Type: ApplicationFiled: June 21, 2002Publication date: February 13, 2003Inventors: Masakazu Ban, Hiroshi Suhara, Masato Horiuchi, Noriyoshi Yamamoto, Hiroshi Enomoto
-
Patent number: 6486194Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.Type: GrantFiled: February 28, 2001Date of Patent: November 26, 2002Assignee: Merck Frosst Canada, Inc.Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
-
Patent number: 6465457Abstract: Fungicidal compounds of formula (I): wherein W is CH3O.Type: GrantFiled: August 18, 1994Date of Patent: October 15, 2002Assignee: Zeneca LimitedInventors: Ian Richard Matthews, Christopher Richard Ayles Godfrey, John Martin Clough
-
Patent number: 6416789Abstract: A wood treatment material having a synergistic combination of fungicides including boron-containing compounds, organo-iodine compounds and amine-oxides is provided. This combination is shown to be especially effective in providing resistance to decay, mold and mildew when wood is treated with this combination. Also provided is wood treated by this combination, and a method of treatment for composite wood.Type: GrantFiled: January 5, 2001Date of Patent: July 9, 2002Assignee: Kop-Coat, Inc.Inventors: Brian Marks, Alan S. Ross, Hans A. Ward
-
Patent number: 6395763Abstract: The present invention relates to novel compounds, methods of preparing these compounds, and pharmaceutical compositions comprising these compounds. These compounds are carbamate prodrugs that convert to active inhibitors of the IMPDH enzyme in vivo. The compounds and pharmaceutical compositions of this invention are particularly well suited for activation and subsequent inhibition of the IMPDH enzyme activity. Consequently, these prodrugs may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds and compositions of this invention.Type: GrantFiled: June 23, 2000Date of Patent: May 28, 2002Assignee: Vertex Pharmaceuticals IncorporatedInventors: Dean P. Stamos, Randy S. Bethiel
-
Patent number: 6346545Abstract: The present invention relates to urethanes and the thio and dithio analogues thereof of general formula wherein m, n, A, X, Y and R1 to R8 are defined as in claim 1, the enantiomers, diastereomers and the salts thereof, particularly the physiologically acceptable acid addition salts thereof which have valuable properties, particularly an inhibitory effect on cholesterol biosynthesis, pharmaceutical compositions containing these compounds, their use and processes for preparing them.Type: GrantFiled: March 24, 1999Date of Patent: February 12, 2002Assignee: Boehringer Ingelheim Pharma KGInventors: Roland Maier, Rudolf Hurnaus, Michael Mark, Bernhard Eisele, Peter Mueller, Gebhard Adelgoss, Gebhard Schilcher
-
Patent number: 6342624Abstract: Compounds characterized generally as propargyl glycine amino propargyl diol derivatives are useful for treatment of a disorder mediated by inhibiting plasma renin activity.Type: GrantFiled: January 6, 2000Date of Patent: January 29, 2002Assignee: G. D. Searle & Co.Inventors: Gunnar J. Hanson, John S. Baran
-
Patent number: 6251938Abstract: This invention is directed to compounds of the following formula: wherein m is from 0-4; X is O or S; Y is halogeno; R1 is hydrogen or C1-4 alkyl; R2 is hydrogen, C1-4 alkyl or optionally substituted propargyl; and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 cycloalkyl or C6-12 aralkyl, R5 is hydrogen or C1-4 alkyl; and pharmaceutically acceptable salts thereof, provided that when X is O, R2 is optionally substituted propargyl. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: June 18, 1999Date of Patent: June 26, 2001Assignees: Teva Pharmaceutical Industries, Ltd.,, Technion Research and Development Foundation, Ltd.,, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B. H. Youdim
-
Patent number: 6197805Abstract: This invention is directed to a broad spectrum antimicrobial composition which comprises a mixture of an iodopropynyl compound in combination with 2-(methoxycarbonylamino)benzimidazole and, where desirable, an algicide said mixture provided in an amount sufficient to protect a substrate from attack by one or more organisms. The composition can be used broadly in industrial systems and more particularly with substrates such as paints, coatings, stucco, concrete, stone, cementaceous surfaces, wood, caulking, sealants, textiles, leather, wood, preservatives, metal working fluids, drilling muds, clay slurries, glazes, optical brightness, carpet backing, pigments and as a preservative for other aqueous and wet state products, and the like.Type: GrantFiled: May 27, 1999Date of Patent: March 6, 2001Assignee: Troy Technology Corporation, Inc.Inventor: Roger Errol Smith
-
Patent number: 6063761Abstract: The invention provides an analogue of a pharmaceutical active whose molecular weight is less than 25,000 Daltons, the analogue comprising a pharmaceutical active whose molecular weight is less than 25,000 Daltons covalently linked to a pendant molecular group wherein as a result of the administration of the composition to the human or animal body an active complex having a molecular weight of 25,000 Daltons or greater is present in the human or animal circulatory system. The analogue is hepatoselective when administered to the circulatory system. Preferably the analogue is an insulin analogue comprising an insulin or functional equivalent thereof covalently linked to the pendant molecular group wherein the active complex is an insulin complex. Such an insulin analogue may be used in a method of insulin replacement therapy.Type: GrantFiled: June 15, 1998Date of Patent: May 16, 2000Assignees: Kings College London, Deutsches Wollforschuncsinstitut an der Rwth AachenInventors: Richard Henry Jones, Fariba Shojaee-Moradi, Peter Henri Sonksen, Dietrich Brandenburg, Achim Schuttler, Heike Eckey
-
Patent number: 5973000Abstract: The invention relates to a hair revitalizing tonic composition containing, as an active ingredient, at least one lipid derivative of the general formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and Y are as defined in the specification, and a and b are 0 or 1, as well as its use. Thus, there is provided a hair revitalizing tonic composition having an excellent hair loss prevention and hair revitalizing effect and, moreover, an excellent dandruff and itchy scalp prevention effect.Type: GrantFiled: June 3, 1997Date of Patent: October 26, 1999Assignees: Shiseido Company, Ltd., Takeda Chemical Industries, Ltd.Inventors: Tsunao Magara, Yoshiharu Tsuji, Chika Hamada, Yosuke Nakazawa, Eriko Takeoka, Masahiro Tajima, Masazumi Watanabe
-
Patent number: 5942548Abstract: Compounds characterized generally as ethynyl alanine amino diol derivatives are useful as renin inhibitors for the treatment of cardiovascular disorders. Compounds of particular interest are those of Formula I ##STR1## wherein A is selected from CO and SO.sub.2 wherein X is selected from oxygen atom and methylene; wherein each of R.sub.1 and R.sub.9 is a group independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, benzyl, .beta.,.beta.,.beta.-trifluoroethyl, t-butyloxycarbonyl and methoxymethylcarbonyl, and wherein the nitrogen atom to which R.sub.1 and R.sub.9 are attached may be combined with oxygen to form an N-oxide; wherein R.sub.2 is selected from hydrido, methyl, ethyl and isopropyl; wherein R.sub.3 is selected from benzyl, cyclohexylmethyl, phenethyl, imidazolemethyl, pyridylmethyl and 2-pyridylethyl; wherein R.sub.5 is propargyl or a propargyl-containing moiety; wherein R.sub.7 is cyclohexylmethyl; wherein each of R.sub.4 and R.sub.Type: GrantFiled: March 24, 1998Date of Patent: August 24, 1999Assignee: G.D. Searle & Co.Inventors: Gunnar J. Hanson, John S. Baran
-
Patent number: RE39055Abstract: The invention provides an analogue of a pharmaceutical active whose molecular weight is less than 25,000 Daltons, the analogue comprising a pharmaceutical active whose molecular weight is less than 25,000 Daltons covalently linked to a pendant molecular group wherein as a result of the administration of the composition to the human or animal body an active complex having a molecular weight of 25,000 Daltons or greater is present in the human or animal circulatory system. The analogue is hepatoselective when administered to the circulatory system. Preferably the analogue is an insulin analogue comprising an insulin or functional equivalent thereof covalently linked to the pendant molecular group wherein the active complex is an insulin complex. Such an insulin analogue may be used in a method of insulin replacement therapy.Type: GrantFiled: May 15, 2002Date of Patent: April 4, 2006Assignee: BTG International LimitedInventors: Richard Henry Jones, Fariba Shojaee-Moradi, Peter Henri Sonksen, Dietrich Brandenburg, Achim Schuttler, Heike Eckey